This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cardiometabolic Drugs Market

Cardiometabolic Drugs Market by Indication Type, Drug Class, Distribution Channel & Region - Forecast 2022 - 2032

Market Insights on Cardiometabolic Drugs covering sales outlook, demand forecast & up-to-date key trends

Cardiometabolic Drugs Market Outlook

The global cardiometabolic drugs market size reached US$ 50 Bn in 2021. The sales of cardiometabolic drugs are estimated to surpass a valuation of US$ 70 Bn by 2032, rising at a CAGR of 4% to 5% during the forecast period 2022-2032. Driven by the rising emphasis on the development of novel drugs that offers better results with minimal side effects, the demand for cardiometabolic drugs is projected to top US$ 55 Bn by 2022.

Report Attribute

Details

Cardiometabolic Drugs Market Base Year Value (2021)

US$ 50 Billion

Cardiometabolic Drugs Market Expected Value (2022)

US$ 55 Billion

Cardiometabolic Drugs Market Anticipated Value (2032)

US$ 70 Billion

Cardiometabolic Drugs Market Projected Growth Rate (2022-2032)

4% to 5% CAGR

Cardiometabolic drugs are therapeutics medications purposefully used for a vast composition of metabolic disorders and dysfunction including cardiovascular diseases, obesity, diabetes, hypertension, dyslipidemia, central adiposity, and others.

What are the Prominent Factors Augmenting the Demand for Cardiometabolic Drugs in the Market

Due to increasing fast-paced lifestyles, changing eating habits, and rising stress levels, a substantial rise in the burden of lifestyle diseases such as diabetes, obesity, hypertension, and others is being witnessed, creating demand for treatment drugs.

For instance, according to the International Diabetic Foundation, nearly 537 million adults between the age of 20 to 79 are living with diabetes across the world and the number is estimated to reach 643 million by 2030. As cardiometabolic disorders are extensively used by diabetic patients for diverse applications, such as insulin resistance, growing diabetic population is projected to create high remunerative opportunities in the global market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which are Key Challenges Restraining the Growth in the Global Cardiometabolic Drugs Market

There are number of side effects associated with the consumption of cardiometabolic drugs such as antidiabetics, anticoagulants, hypertension, dyslipidemia drug, and others such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Hence, rising awareness regarding such severe adverse effects on health is hindering the sales of cardiometabolic drugs in the market.

Why is North America Garnering Maximum Sales of Cardiometabolic Drugs in the Global Market

As per Future Market Insights, North America is forecast to account for the lion’s share in the global cardiometabolic drugs market between 2022 and 2032.

Cardiometabolic disorders and conditions involve a group of abnormalities that are interrelated, leading to a diverse constellation of cardiometabolic drugs used for each indication to limit the disease effect.

The prevalence of cardiovascular diseases is rising at a rapid pace across North America, due to the increasing pollution, smoking, opioid use, and others. According to the Centers for Disease Control and Prevention, nearly 18.2 million adults or around 6.7% of the population across the U.S. have coronary heart disease.

As cardiometabolic drugs play a crucial role in limiting the effect of these diseases along with their treatments, increasing burden of cardiovascular diseases is estimated to bolster the sales in the North America market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is South Asia Contributing to the Growth in the Global Cardiometabolic Drugs Market

FMI reveals that South Asia is anticipated to emerge as a highly lucrative market for cardiometabolic drugs during the forecast period 2022-2032.

With growing trend of personalized medication and rising demand for more effective drugs with minimal to no side effects, key manufacturers are focusing on research and development activities for the development of novel drugs.

For instance, in 2020, Natco Pharma, an Indian multinational pharmaceutical company announced launching a novel anti-blood clot medication, Rivaroxaban, under the brand name Xarelto. A multiplicity of such new product launches are expected to favor the demand for cardiometabolic drugs in the South Asia market.

Market Competition

Some of the leading players in the cardiometabolic drugs market are AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others.

Attributed to the presence of such high number of participants and increasing emphasis on the development and launch of for novel drugs, the market is highly competitive.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Report Scope

Report Attribute

Details

Growth Rate       

CAGR of 4% to 5% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Class
  • Indication Type
  • Distribution Channel
  • Region

Countries Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Companies Profiled

  • Novartis
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Bayer HealthCare Pharmaceuticals Inc.
  • Par Pharmaceutical
  • Romark Laboratories, L.C.
  • Lupin Pharma
  • Schering Corporation
  • Others

Customization

Available Upon Request

Key Segments Profiled in the Cardiometabolic Drugs Market Survey

By Drug Class:

  • Weight Loss Drugs
  • Antidiabetics Drugs
  • Anticoagulants Drugs
  • Antiplatelet Drugs
  • Impaired Glucose Tolerance Drugs
  • Insulin Resistance Drugs
  • Hypertension Drugs
  • Dyslipidemia Drugs
  • Others

By Indication Type:

  • Congestive Heart Failure
  • Hypertension
  • Diabetes
  • Obesity
  • Others

By Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Clinics
  • Retail Sales
  • Retail Pharmacies
  • E- Commerce/Mail Order Pharmacies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

FMI projects the sales of cardiometabolic drugs in the market is expected to rise at 4% to 5% value CAGR by 2032

The global cardiometabolic drugs market is expected to be dominated by North America over the forecast period 2022-2032.

AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others are some of the leading players in the key cardiometabolic drugs market.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Vaginitis Treatment Drugs Market

Published : July 2020

Healthcare

Anti-Viral Drugs Market

Published : October 2016

Healthcare

Orphan Drugs Market

Published : February 2016

Healthcare

General Anesthesia Drugs Market

Published : August 2015

Google translate

Cardiometabolic Drugs Market